样式: 排序: IF: - GO 导出 标记为已读
-
Long-term impact of COVID-19 pandemic on antibiotic use in primary care: lessons to optimize antimicrobial use Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-11 Thais de Pando, Santiago Grau, Alexander Almendral, Daniel Echeverría-Esnal, Sergi Hernández, Enric Limon, Caridad Pontes
Lockdowns due to the COVID-19 pandemic was associated with changes in the pattern of use of antimicrobials, but persistence of changes after lockdowns has not been described. The objective was to d...
-
Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-09 Jun-Hyung Cho
This study aimed to investigate the efficacy of bismuth added to a 2-week triple therapy consisting of tegoprazan (TPZ), amoxicillin, and clarithromycin for first-line Helicobacter pylori eradicati...
-
Personalized care approaches to hepatitis C therapy: recent advances and future directions Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-08 Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile
The introduction of direct-acting antivirals (DAAs) has significantly transformed the therapeutic landscape for chronic C hepatitis virus (HCV) infection. However, there is still room for further i...
-
Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-08 Antonio Gallardo-Pizarro, Olivier Peyrony, Mariana Chumbita, Patricia Monzo-Gallo, Tommaso Francesco Aiello, Christian Teijon-Lumbreras, Emmanuelle Gras, Josep Mensa, Alex Soriano, Carolina Garcia-Vidal
Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the management of febrile neutropenia (FN) and drive progress toward personalized medicine.In this review,...
-
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-08 Behnam Amani, Bahman Amani
This study aims to compare the effectiveness and safety of nirmatrelvir/ritonavir (Paxlovid) and sotrovimab for coronavirus disease 2019 (COVID-19).A search was conducted on PubMed, Cochrane Librar...
-
Comparing prolonged infusion to intermittent infusion strategies for beta-lactam antibiotics in patients with gram-negative bacterial infections: a systematic review and meta-analysis Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-05 Chih-Chung Lin, Jheng-Yen Wu, Po-Yu Huang, Hui-Lin Sung, Yu-Chun Tung, Chih-Cheng Lai, Yu-Feng Wei, Pin-Kuei Fu
Our objective is to determine whether prolonged infusion (PI) of beta-lactam antibiotics yields superior outcomes compared to intermittent infusion (II) in patients with Gram-Negative Bacterial (GN...
-
Antibiotic stewardship: following in the footsteps of Nordic countries? Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-03-04 Niels Frimodt-Møller, Frederik Boetius Hertz
Published in Expert Review of Anti-infective Therapy (Ahead of Print, 2024)
-
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-26 Akihiro Ohmoto, Shigeo Fuji
Cytomegalovirus (CMV) infection remains a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While conventional antiviral agents such as ganciclovir can be use...
-
Is the world crippled by antimicrobial resistance, or simply lacking information? Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-21 Ahmad Z. Al Meslamani
Published in Expert Review of Anti-infective Therapy (Just accepted, 2024)
-
A multifaceted strategy is needed to limit the over-the-counter sale of antimicrobials Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-21 Carl Llor, Ana Moragas
Published in Expert Review of Anti-infective Therapy (Just accepted, 2024)
-
Clinical utility of procalcitonin in implementation of procalcitonin-guided antibiotic stewardship in the South-East Asia and India: evidence and consensus-based recommendations Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Andrea Lay-Hoon Kwa, Brigitte Rina Aninda Sidharta, Do Ngoc Son, Kapil Zirpe, Petrick Periyasamy, Rongpong Plongla, Subramanian Swaminathan, Tonny Loho, Vu Van Giap, Anucha Apisarnthanarak
The South-East Asian (SEA) region and India are highly susceptible to antibiotic resistance, which is caused due to lack of antimicrobial stewardship (AMS) knowledge, uncontrolled use of antibiotic...
-
Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, Chih-Cheng Lai, Chun-Yen Huang
This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs).Patients with underlying CVDs...
-
Immunocompromised patients and COVID-19: how do we protect those most at risk? Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Jochen Schneider, Johanna Erber, Lutz Renders, Christoph D. Spinner
Published in Expert Review of Anti-infective Therapy (Vol. 22, No. 1-3, 2024)
-
Could Herpesviridae be the cause of severe acute hepatitis of unknown origin in children? Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Livia Melo Villar, Lucas Lima da Silva, Barbara Vieira do Lago, Jessica Gonçalves Pereira, Ana Carolina Silva Guimarães, Francisco Campello do Amaral Mello, Vanessa Salete de Paula
Severe acute hepatitis (SAH) is defined by a severe inflammation of hepatocytes in the liver parenchyma which can lead to an acute liver failure, a clinical condition with high mortality rate that ...
-
Phage therapy: resurrecting a historical solution for the contemporary challenge of rising antibiotic resistance in Latin America Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Justin Yeager, Ana María Gómez-Jaramillo, Esteban Ortiz-Prado, Manuel Calvopiña, Benjamin K. Chan
Antimicrobial resistance in Latin America is a growing concern in both human and non-human animal populations. The economic burden that is likely to be imposed through increased resistance will cau...
-
Carbapenem-resistant Klebsiella pneumoniae: the role of plasmids in emergence, dissemination, and evolution of a major clinical challenge Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Vincenzo Di Pilato, Simona Pollini, Vivi Miriagou, Gian Maria Rossolini, Marco Maria D’Andrea
Klebsiella pneumoniae is a major agent of healthcare-associated infections and a cause of some community-acquired infections, including severe bacteremic infections associated with metastatic absce...
-
Low-risk penicillin allergy delabeling: a scoping review of direct oral challenge practice, implementation, and multi-disciplinary approaches Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Elise Mitri, Gemma Reynolds, Catherine J Hornung, Jason A Trubiano
Penicillin allergy is common, and there is increased clinician interest in direct oral challenge (DOC) as a testing strategy for low-risk penicillin allergy. To aid wider implementation of DOC, con...
-
Understanding Staphylococcus aureus internalisation and induction of antimicrobial tolerance Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Frédéric Goormaghtigh, Françoise Van Bambeke
Staphylococcus aureus, a human commensal, is also one of the most common and serious pathogens for humans. In recent years, its capacity to survive and replicate in phagocytic and non-phagocytic ce...
-
Health literacy, knowledge, household disposal, and misuse practices of antibiotics among UAE residents: a nationwide cross-sectional study Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Zelal Kharaba, Sayer Al-Azzam, Shoroq M. Altawalbeh, Alin Alkwarit, Noor Abdulkareem Salmeh, Yassen Alfoteih, Mohammad Araydah, Reema Karasneh, Mamoon A Aldeyab
The study aimed to evaluate health literacy, knowledge, household disposal, and misuse practices of antibiotics among the United Arab Emirates (UAE) residents.An observational cross-sectional study...
-
Impact of a multidisciplinary antimicrobial stewardship program on antibiotic utilization and clinical outcomes at a tertiary hospital in Saudi Arabia: a quasi-experimental study Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-12 Khadijah A. Sarkhi, Khalid Eljaaly, Reham Kaki, Rahaf Bahamdan, Sultan A. Alghamdi, Mohammed O. Baharith, Abrar K. Thabit
This study aims to assess the impact of a multidisciplinary antimicrobial stewardship program (ASP) intervention on various metrics.A quasi-experimental study was performed on non-ICU patients for ...
-
An assessment of the index of rational drug prescribing for severe acute respiratory infections among hospitalised children in Northern Nigeria: a retrospective study Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-09 Aliyu Sulaiman, Mohammad Alfa Isah, Abubakar Usman
This study evaluated drug use pattern among hospitalized children with severe acute respiratory infection (SARI) in Nigeria.A retrospective assessment of prescribed medicines for children aged 13 y...
-
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-02-01 Pulin Li, Ling Huang, Rui Han, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang
Since December 2022, the Omicron variant has led to a widespread pandemic in China. The study was to explore the safety and effectiveness of Paxlovid for the treatment of coronavirus disease 2019 (...
-
Prevalence of antibiotic resistance in clinical isolates of M. kansasii: a systematic review and meta-analysis Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-31 Negar Narimisa, Forough Goodarzi, Narjess Bostanghadiri, Faramarz Masjedian Jazi
The prevalence of diseases caused by non-tuberculous mycobacteria (NTM), including M. kansasi, is increasing, necessitating further information to guide prevention, control, and treatment strategie...
-
The clinical application of traditional Chinese medicine NRICM101 in hospitalized patients with COVID-19 Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-30 Wen-Kuei Chang, Chieh-Jen Wang, Tung-Hu Tsai, Fang-Ju Sun, Chao-Hsien Chen, Kuan-Chih Kuo, Hsin-Pei Chung, Yen-Hsiang Tang, Yen-Ting Chen, Kuo-Lun Wu, Jou-Chun Wu, Chang-Yi Lin, Hai-Bo Zhang
The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19.We conducted a retrospective study from April 20 to 8 July 2021, and evaluated the saf...
-
Biosimilars as antivirals: opportunities and challenges Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-30 Anan S. Jarab, Shrouq R Abu Heshmeh, Ahmad Z. Al Meslamani
Published in Expert Review of Anti-infective Therapy (Ahead of Print, 2024)
-
Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed metallo-β-lactamase production: a systematic review and meta-analysis Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-23 Nitin Gupta, Carl Boodman, Parikshit Prayag, Abi Manesh, Tirlangi Praveen Kumar
Carbapenem-resistant Enterobacterales (CRE) due to Metallo-β-lactamase (MBL) production are treated with either polymyxins or the novel combination of ceftazidime-avibactam and aztreonam (AA). This...
-
Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-26 Johnny Zakhour, L’Emir Wassim El Ayoubi, Souha S. Kanj
Metallo-beta-lactamases (MBLs) are responsible for resistance to almost all beta-lactam antibiotics. Found predominantly in Gram-negative bacteria, they severely limit treatment options. Understand...
-
Healthcare professionals’ understanding and perception of drug-related issues linked to off-label pharmacological medications used for COVID-19 Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-24 Muhammad Zeeshan Munir, Amer Hayat Khan, Tahir Mehmood Khan
To evaluate the opinions of healthcare workers regarding drug therapy problems linked to anti-infective medicines used for the treatment of COVID-19 infection in Pakistan.This cross-sectional study...
-
Drug recommendation for optimization on treatment outcome for MDR/RR-TB based on a multi-center, large scale, retrospective cohort study in China Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-22 Lin Fan, Ming Yang, Yu-Tong Han, Fei Ren, Hua Wang, Jin-Bao Ma, Guo-Hui Zhu, Yan-Jun Xiong, Xin-Xin Fan, Su-Xia Chen, Hao-Yu Wu, Wen-Wen Sun, Shao-Jun Zhang, Hui Ke, Xiao-Hong Cheng, Biao Xu, Yu Chen, Chang Chen
With the change in drug-resistant pattern, MDR/RR-TB was faced with underlying changes in regimens. A multi-center, large-scale, retrospective study performed aims to provide a recommendation of dr...
-
Reviewing novel treatment options for carbapenem-resistant Enterobacterales Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-10 Natalie A Mackow, David van Duin
Carbapenem resistant Enterobacterales (CRE) are a major threat to global health and hospital-onset CRE infections have risen during the COVID-19 pandemic. Novel antimicrobials are now available for...
-
Predictors and patterns of empirical antibiotic therapy and associated outcomes in COVID-19 patients: a retrospective study in a tertiary care facility in South India Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-08 Lipin Lukose, Gursimran Kaur, Mohammed Asif M, Gail Ann Abraham, Kanav Khera, Subeesh K Viswam, Ronald L Castelino, Shubhada Karanth, Chandrashekar Udyavara Kudru, Muralidhar Varma, Sonal Sekhar Miraj
The coronavirus disease (COVID-19) led to a global health crisis, especially affecting low- and middle-income countries like India. Inappropriate use of antibiotics in COVID-19 patients has been a ...
-
Waking up to the Naegleria threat: urgent measures needed to protect public health in Pakistan Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-09 Ifrah Ata, Nabeel Riaz, Fariah Ata, Umer Farooq, Tauqeer Hussain Mallhi
Published in Expert Review of Anti-infective Therapy (Ahead of Print, 2024)
-
The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID-19 Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2024-01-04 Jheng-Yan Wu, Mei-Yuan Liu, Mei-Chuan Lee, Kuo-Chuan Hung, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Shu-Ching Tseng, Chih-Ying Lu, Chih-Cheng Lai
This study investigated the outcomes ofunderweight patients with COVID-19 and the effectiveness of antiviral agents inthis population.A retrospective cohort study using theTriNetX research network ...
-
Bacterial Co-infections, secondary Infections and antimicrobial use among hospitalized COVID-19 patients in the sixth wave in Pakistan: findings and implications Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-12-26 Zia Ul Mustafa, Arfa Batool, Hadia Ibrar, Muhammad Salman, Yusra Habib Khan, Tauqeer Hussain Malhi, Johanna C. Meyer, Brian Godman, Catrin E. Moore
Previous studies in Pakistan have shown considerable over prescribing of antibiotics in patients hospitalized with COVID-19 despite very low prevalence of bacterial infections. Irrational use of an...
-
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-12-06 Lin Gan, Xiaoxin Xie, Yanhua Fu, Yebing Song, Chunli Song, Tingting Ren, Hai Long
This study aimed to evaluate the therapeutic effect and tolerance of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) use for 24 weeks in anti-retroviral therapy (ART)-naïve p...
-
Antibiotic resistance in low- and middle-income countries: current practices and its global implications Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Ahmad Z. Al Meslamani
Antibiotic consumption rates are high in both high and low-income countries, but addressing antibiotic practices in low- and middle-income countries (LMICs) is crucial to combatting antibiotic resi...
-
Selling antibiotics without prescriptions among community pharmacies and drug outlets: a simulated client study from Ghana Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Eric Kofi Ngyedu, Joseph Acolatse, George Akafity, Robert Incoom, Audu Rauf, R Andrew Seaton, Jacqueline Sneddon, Elaine Cameron, Margaret Watson, Marta Wanat, Brian Godman, Amanj Kurdi
Selling antibiotics without prescriptions is mostly illegal worldwide, including in Ghana, and promotes antimicrobial resistance. We evaluated the prevalence and practice of selling antibiotics wit...
-
Fighting with brain-eating amoeba: challenges and new insights to open a road for the treatment of Naegleria fowleri infection Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Siva Nageswararao Gajula, Lakshmi Vineela Nalla
Published in Expert Review of Anti-infective Therapy (Vol. 21, No. 12, 2023)
-
Practical diagnostic algorithms for Chagas disease: a focus on low resource settings Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Juan Carlos Gabaldón-Figueira, Malia Skjefte, Silvia Longhi, Elisa Escabia, Lady Juliette García, Albert Ros-Lucas, Nieves Martínez-Peinado, Arturo Muñoz-Calderón, Joaquim Gascón, Alejandro Gabriel Schijman, Julio Alonso-Padilla
Chagas disease, caused by parasite Trypanosoma cruzi, is the most important neglected tropical disease in the Americas. Two drugs are available for treatment, but access to them is challenging, in ...
-
Treating urinary tract infections in the era of antibiotic resistance Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Niels Frimodt-Møller, Lars Bjerrum
Urinary tract infections (UTIs) are associated with 25–40% of antibiotics consumed in primary care and are, therefore, driving antibiotic resistance. The worldwide increase in antibiotic resistance...
-
Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Jack Chang, Ardita Tasellari, Jamie L. Wagner, Marc H. Scheetz
Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in the hospital setting and causes significant morbidity and mortality each year. Since the initial discovery over 6...
-
Part 1: Understanding the role of Malassezia spp. in skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and animal skin Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Iniobong Chukwuebuka Ikenna Ugochukwu, Wafa Rhimi, Wissal Chebil, Antonio Rizzo, Maria Tempesta, Gustavo Giusiano, Raul Fernando Mejía Tábora, Domenico Otranto, Claudia Cafarchia
Malassezia spp. are a group of lipid-dependent basidiomycetes yeasts acting as commensal organisms of the human and animal skin. However, under some not well-defined circumstances, these yeasts may...
-
Advantages and limitations of current diagnostic laboratory approaches in syphilis and congenital syphilis Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Weiping Cao, Phoebe G. Thorpe, Kevin O’Callaghan, Ellen N. Kersh
The reemergence of syphilis, especially congenital syphilis, presents a significant public health threat. Accurate diagnosis of syphilis depends on recognition of a constellation of symptoms, revie...
-
The gut and lung microbiota in pulmonary tuberculosis: susceptibility, function, and new insights into treatment Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Qiqi Zhuo, Xianyi Zhang, Kehong Zhang, Chan Chen, Zhen Huang, Yuzhong Xu
Tuberculosis (TB) is a chronic infectious disease caused by mycobacterium tuberculosis (Mtb) that poses a major threat to human health.Herein, we aim to review the alteration of the microbiota in g...
-
Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Jianhua You, Jiaxin Tian, Haidi Wu, Wenyan Kang, Jianru Wen, Hongwei Xu, Wenbo Shi, Zhi Wang, Hanyu Wei, Yanjun Du, Xiang Li, Guangyuan Mu, Min Zhou, Zhidong Gu, Jieming Qu
By the end of 2022, China had made a pivotal decision to optimize the COVID-19 policy. The dominant Omicron variant in China at that time was highly transmissible. In this study, we aimed to evalua...
-
Prevalence and related factors of non-adherence to antibiotics among the general public: a cross-sectional study in China Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-24 Qinnan Li, Jianxiong Wu, Jing Wang, Yanhong Gong, Xiaoxv Yin
This study aims to assess the prevalence and associated factors of non-adherence to antibiotics (NAA) during COVID-19.A cross-sectional study was conducted from 28 October 2022 to 6 November 2022. ...
-
Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-20 Wen-Wen Sun, Ming Yang, Xiao-Hong Chen, Li-Chao Fan, Hao-Yu Wu, Shao-Jun Zhang, Yu Chen, Lin Fan
The study aimed to observe the efficacy and safety of an all-oral bedaquiline (BDQ)-containing regimen for pediatric multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) through a multicenter, r...
-
Part 2: Understanding the role of Malassezia spp. in skin disorders: pathogenesis of Malassezia associated skin infections Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Iniobong Chukwuebuka Ikenna Ugochukwu, Wafa Rhimi, Wissal Chebil, Antonio Rizzo, Maria Tempesta, Gustavo Giusiano, Raul Fernando Mejía Tábora, Domenico Otranto, Claudia Cafarchia
Malassezia is a major component of the skin microbiome, a lipophilic symbiotic organism of the mammalian skin, which can switch to opportunistic pathogens triggering multiple dermatological disorde...
-
Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720 Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Kevin L. Winthrop, Patrick Flume, Kamal A. Hamed
Nontuberculous mycobacteria infect patients who have structural lung disease or those who are immunocompromised. Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasing in prevalence....
-
An overview of gram-negative bacteria with difficult-to-treat resistance: definition, prevalence, and treatment options Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Jiaju Zhuo, Beibei Liang, Huan Zhang, Yulong Chi, Yun Cai
Difficult-to-treat resistance (DTR) is a newly proposed resistance phenotype characterized by resistance to all first-line drugs. The emergence of DTR as a new resistance phenotype has significant ...
-
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Coleman Rotstein, Joseph P. Lynch III, George G. Zhanel
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) continue to be common infections causing significant morbidity and mortality worldwide. The timely ...
-
Clinical trials aimed at HIV cure or remission: new pathways and lessons learned Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Maya Dyveke Schou, Ole Schmeltz Søgaard, Thomas Aagaard Rasmussen
The main barrier to finding a cure against HIV is the latent HIV reservoir, which persists in people living with HIV (PLWH) despite antiretroviral treatment (ART). Here, we discuss recent findings ...
-
Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Xiuyun Li, Huijun Yang, Ximeng Duan, Min Cui, Wenlan Xing, Shicun Zheng
The limited availability of antifungal drugs for candidiasis and the persistent problem of drug resistance, necessitates the urgent development of new antifungal drugs and alternative treatment opt...
-
How can we tackle the overuse of antibiotics in low- and middle-income countries? Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Giorgia Sulis, Sena Sayood, Sumanth Gandra
Antibiotic overuse is a pressing global health concern, particularly in low- and middle-income countries (LMICs) where there is limited access to quality healthcare and insufficient regulation of a...
-
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-08 Camilla Muccini, Antonella Castagna
Darunavir (DRV)/cobicistat (COBI)/emtricitabine (FTC)/tenofovir alafenamide (TAF) is the only protease inhibitor-based single-tablet regimen (STR) approved for the treatment of HIV infection of adu...
-
Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-11-06 Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long
The efficacy and safety of dolutegravir+lamivudine (DTG +3TC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have been demonstrated in clinical trials of treatment-naïve therapy....
-
Host defense mechanisms against Candida auris Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-10-27 Joseph Pechacek, Michail S. Lionakis
Candida auris is a pathogen of growing public health concern given its rapid spread across the globe, its propensity for long-term skin colonization and healthcare-related outbreaks, its resistance...
-
Identification of antibiotic consumption targets for the management of Clostridioides difficile infection in hospitals- a threshold logistic modelling approach Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-10-27 Mamoon A. Aldeyab, Stuart E. Bond, Ian Gould, Jade Lee-Milner, Joseph J. Spencer-Jones, Achyut Guleri, Adel Sadeq, Feras Jirjees, William J. Lattyak
This study aims to demonstrate the utility of a threshold logistic approach to identifying thresholds for specific antibiotic use associated with Clostridioides difficile infection (CDI) in an Engl...
-
Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-10-27 Wan-Hsuan Hsu, Bo-Wen Shiau, Ting-Hui Liu, Jheng-Yan Wu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai, Chi-Hsing Chen
This retrospective cohort study assessed the clinical effectiveness of nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis(LC).The data of non-hospitalized adul...
-
Current rates of purchasing of antibiotics without a prescription across sub-Saharan Africa; rationale and potential programmes to reduce inappropriate dispensing and resistance Expert Rev. Anti Infect. Ther. (IF 5.7) Pub Date : 2023-10-27 Tiyani Milta Sono, Eugene Yeika, Aislinn Cook, Aubrey Kalungia, Sylvia A. Opanga, Joseph Elikem Efui Acolatse, Israel Abebrese Sefah, Ana Golić Jelić, Stephen Campbell, Giulia Lorenzetti, Zia Ul Mustafa, Vanda Marković-Peković, Amanj Kurdi, Bene D Anand Paramadhas, Godfrey Mutashambara Rwegerera, Adefolarin A Amu, Mobolaji Eniola Alabi, Evelyn Wesangula, Margaret Oluka, Felix Khuluza, Ibrahim Chikowe
Antimicrobial resistance (AMR) is a global concern. Currently, the greatest mortality due to AMR is in Africa. A key driver continues to be high levels of dispensing of antibiotics without a prescr...